Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients

Journal of Hypertension

Volumn 30, Issue 3, 2012, Pages 561-566

  Boschmann, Michael ^a   Nussberger, Jürg ^b   Engeli, Stefan ^c   Danser, A H Jan ^d   Yeh, Ching Ming ^e   Prescott, Margaret F ^e   Dahlke, Marion ^e   Jordan, Jens ^c  

^a FRANZ VOLHARD CLINIC   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

adipose tissue; angiotensin II; direct renin inhibitor; metabolic syndrome; microdialysis; obesity

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN II; PLACEBO; RENIN;

ABDOMINAL OBESITY; ABDOMINAL SUBCUTANEOUS FAT; ABSENCE OF SIDE EFFECTS; ADIPOSE TISSUE; ADULT; ANGIOTENSIN BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; INTERSTITIAL FLUID; MALE; MICRODIALYSIS; MUSCLE BIOPSY; OBESITY; OPEN STUDY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SKELETAL MUSCLE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84857042068     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834f6b43     Document Type: Conference Paper

References (26)

1. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67:1767-1792. (Pubitemid 47263181)
2. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52:130-136.
3. Azizi M. Direct renin inhibition: clinical pharmacology. J Mol Med (Berl) 2008; 86:647-654.
4. Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008; 52:1076-1083.
5. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49:1157-1163. (Pubitemid 46400330)
6. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24:93-103.
7. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-362. (Pubitemid 40315803)
8. Habibi J, Whaley-Connell A, Hayden MR, DeMarco VG, Schneider R, Sowers SD, et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008; 149:5643-5653.
9. Lastra G, Habibi J, Whaley-Connell AT, Manrique C, Hayden MR, Rehmer J, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150:2561-2568.
10. Jordan J, Engeli S, Boye SW, Le BS, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49:1047-1055. (Pubitemid 351664315)
11. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009; 27:1493-1501.
12. Jordan J, Tank J, Stoffels M, Franke G, Christensen NJ, Luft FC, et al. Interaction between beta-adrenergic receptor stimulation and nitric oxide release on tissue perfusion and metabolism. J Clin Endocrinol Metab 2001; 86:2803-2810. (Pubitemid 32545743)
13. Stahle L, Segersvard S, Ungerstedt U. A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis. J Pharmacol Methods 1991; 25:41-52.
14. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52:942-947. (Pubitemid 36384264)
15. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985; 7 (3 Pt 2):I1-I7.
16. Nussberger J, Fasanella DT, Porchet M, Waeber B, Brunner DB, Brunner HR, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987; 9:39-44. (Pubitemid 17212750)
17. Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008; 51:15-18. (Pubitemid 350307093)
18. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308:698-705. (Pubitemid 36976519)
19. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73:1419-1425. (Pubitemid 351770494)
20. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15:3126-3133. (Pubitemid 39578845)
21. Azizi M, Menard J, Bissery A, Guyene TT, Bura-Riviere A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007; 2:947-955.
22. Fisher ND, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117:3199-3205.
23. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39:E1-E8.
24. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32:1873-1879.
25. van den Meiracker AH, Man In't Veld AJ, Admiraal PJJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992; 10:803-812.
26. Cappuccio FP, Markandu ND, Sagnella GA, Singer DR, Buckley MG, Miller MA, et al. Effects of amlodipine on urinary sodium excretion, renin-angiotensin- aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991; 5:115-119.